Earnings call transcript: Amgen Q1 2026 beats expectations, raises guidance

Amgen reported Q1 2026 EPS of $5.15 versus $4.80 expected and revenue of $8.62B versus $8.59B expected, then raised full-year guidance to $37.1B-$38.5B in revenue and $21.70-$23.10 non-GAAP EPS. Key growth products such as Repatha (+34%), Evenity (+27%), Tezspire (+20%), and Uplizna (+188%) supported 4% product sales growth, while aftermarket shares rose 2.39%. Management also highlighted strong free cash flow of $1.5B, a 6% dividend increase, ongoing AI-driven efficiency gains, and a potential tax litigation overhang.

Analysis

AMGN is doing the most important thing a post-patent-exposure platform can do: proving that the replacement franchise is not a single-product story but a self-funded pipeline-and-commercial flywheel. The operating lever that matters is mix: if the newer growth assets continue compounding in the high-20s while legacy erosion is managed, the market will likely re-rate AMGN on durability rather than on near-term EPS optics. That makes the stock less about quarterly beats and more about whether management can keep reinvesting at attractive incremental returns without letting the margin structure drift.

The hidden bull case is that the company is seeding multiple optionalities that are each capable of becoming category anchors, which is unusual for a large-cap biotech trading like a mature cash generator. MariTide is the clearest potential multiple-expansion catalyst because convenience can matter as much as efficacy in chronic obesity; if the switching data are credible, the product can attack discontinuation and prior-therapy inertia, not just initial starts. In parallel, the cardiovascular stack creates a second path to upside: if primary-prevention penetration improves and Lp(a) testing broadens, AMGN can convert physician familiarity into a much larger screening-and-treatment funnel over 12-24 months.

The main bear case is not the pipeline; it is execution fragmentation. The tax dispute is a low-probability/high-severity overhang that can compress the multiple if investors start capitalizing a punitive cash-flow haircut, while biosimilar erosion could accelerate faster than models assume once price competition becomes visible in more channels. There is also a non-obvious risk that the market over-credits MariTide before phase III de-risks tolerability persistence; if weight-loss discontinuation remains high across the class, a convenience narrative alone won’t rescue share.

Consensus may be underappreciating how much AMGN benefits from being one of the few large caps that can monetize AI in both discovery and operations, not just as a slideware theme. If the company can sustain its trial-enrollment and manufacturing-efficiency gains, that is a structural margin offset to rising R&D intensity, which makes the guidance raise more durable than a simple demand beat. In that sense, the story is less ‘legacy pharma with a good quarter’ and more ‘platform company with visible capital allocation discipline.’

Key Decisions for Investors

• Long AMGN vs. short NVS or SNY over the next 3-6 months: AMGN has cleaner growth self-help and more visible pipeline monetization; target a 8-12% relative outperformance if MariTide and cardiovascular cadence stays constructive.
• Buy AMGN on any 2-3% pullback after the initial post-earnings move, using a 3-6 month horizon: the guidance reset and multiple growth vectors should keep downside supported unless tax litigation re-prices.
• Consider AMGN Jan-2027 call spreads to express pipeline optionality with limited premium burn: best risk/reward if MariTide switching data and IMDELLTRA expansion read through positively over the next 2-4 quarters.
• Pair long AMGN / short a basket of single-asset obesity names into MariTide data: AMGN’s diversified base reduces binary risk, while peers remain more exposed to a single readout and commercial execution risk.
• If tax litigation headlines worsen, hedge with a short-dated put spread rather than selling core equity: the stock can absorb fundamental noise, but a legal shock could create a fast 5-8% de-rating window.